# Junta clínica — PT-pseudo_6b6ee002f75d (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_6b6ee002f75d",
  "pid": "PT-pseudo_6b6ee002f75d",
  "task": 1,
  "psa": 6.22,
  "age": 65,
  "months": 3,
  "pirads": "5",
  "psad": 0.17,
  "psav": 1.14,
  "psap": 5.6,
  "vol": 36.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.86727,
  "medhx": "Hypertension, Chronic kidney disease",
  "meds": "amlodipine, valsartan",
  "notes": "PSA 6.22 ng/mL. PI-RADS 5. PSAD 0.17. Prostate volume 36 mL. DRE nodus. csPCa 0.87.",
  "pmhx": [
    "Hypertension",
    "Chronic kidney disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "75 kg",
    "height": "177 cm",
    "bmi": "23.9",
    "bp": "127/68 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (17 pack-yr, quit 2001)",
    "last_dental": "3 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "12 Jan 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical review requested after previous biopsy confirmed high-grade malignancy alongside recent PSA escalation."
    },
    {
      "s": "History",
      "t": "A 65-year-old retired truck driver has been monitored since the initial PSA elevation was detected in 2022. He resides with his unmarried partner and maintains a vigorous routine, including twice-weekly tennis matches and roughly three units of alcohol weekly. Past medical history encompasses hypertension and stage 3 chronic kidney disease, currently controlled with amlodipine and valsartan. Tobacco use ceased in 2001 following a 17 pack-year exposure. He denies any current urinary complaints, registering an IPSS score of zero. Recent primary care visits included a seasonal influenza vaccination alongside a dermatological screening for a routine actinic keratosis. A decades-old right knee meniscus tear occasionally causes mild aching during cold spells but imposes no functional restrictions. Due to mild hearing impairment, he requests written documentation for all clinical updates."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: A firm, discrete nodule measuring roughly 1 cm in diameter is palpable within the right peripheral zone, while overall gland symmetry remains intact. General inspection reveals no abnormalities; vital parameters record a blood pressure of 127/68 mmHg and a heart rate of 72 bpm. Cognitive status is alert and oriented. Body mass index registers at 23.9 kg/m2. The patient acknowledges mild hearing impairment yet demonstrates clear comprehension of all procedural directives."
    }
  ],
  "occupation": "retired truck driver",
  "marital": "Living with partner (unmarried)",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "GP practice nurse — flu vaccination",
    "Dermatology — actinic keratosis check"
  ],
  "alcohol": "3 units / week",
  "exercise": "Tennis 2x/week",
  "ipss": "IPSS score: 0/35 (mild LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_6b6ee002f75d
Task: 1

Encounter: Urology - outpatient on 12 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 6.22 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.17 ng/mL²
  - PSA velocity: 1.14 ng/mL/yr
  - Prior PSA: 5.6 ng/mL
  - Prostate volume: 36.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.86727 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Chronic kidney disease
  - Problem list / PMHx: Hypertension, Chronic kidney disease
  - Current medication: amlodipine, valsartan
  - Allergies: NKA
  - Additional notes: PSA 6.22 ng/mL. PI-RADS 5. PSAD 0.17. Prostate volume 36 mL. DRE nodus. csPCa 0.87.

Vitals: weight 75 kg, height 177 cm, BMI 23.9, BP 127/68 mmHg, HR 72 bpm. Smoking: Ex-smoker (17 pack-yr, quit 2001).

Chief complaint: Clinical review requested after previous biopsy confirmed high-grade malignancy alongside recent PSA escalation.

History: A 65-year-old retired truck driver has been monitored since the initial PSA elevation was detected in 2022. He resides with his unmarried partner and maintains a vigorous routine, including twice-weekly tennis matches and roughly three units of alcohol weekly. Past medical history encompasses hypertension and stage 3 chronic kidney disease, currently controlled with amlodipine and valsartan. Tobacco use ceased in 2001 following a 17 pack-year exposure. He denies any current urinary complaints, registering an IPSS score of zero. Recent primary care visits included a seasonal influenza vaccination alongside a dermatological screening for a routine actinic keratosis. A decades-old right knee meniscus tear occasionally causes mild aching during cold spells but imposes no functional restrictions. Due to mild hearing impairment, he requests written documentation for all clinical updates.

Physical examination: Per rectum: A firm, discrete nodule measuring roughly 1 cm in diameter is palpable within the right peripheral zone, while overall gland symmetry remains intact. General inspection reveals no abnormalities; vital parameters record a blood pressure of 127/68 mmHg and a heart rate of 72 bpm. Cognitive status is alert and oriented. Body mass index registers at 23.9 kg/m2. The patient acknowledges mild hearing impairment yet demonstrates clear comprehension of all procedural directives.

Patient info: retired truck driver; Living with partner (unmarried); Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 3 units / week; exercise Tennis 2x/week; IPSS score: 0/35 (mild LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Dermatology — actinic keratosis check.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.48
  uncertainty  +/- 0.10 epistemic (95% band 0.27-0.68); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.35: PI-RADS 5, PSA 6.9, PSAD 0.171, age 67, DRE Nodus -> DEFER (borderline). He wrote: "Need to know if the P5 lesion has grown in size. If not no biopsy."
  2. distance 0.44: PI-RADS 5, PSA 8.3, PSAD 0.215, age 66, DRE Suspicious -> DEFER (clear). He wrote: "This person should discuss curative treatment (younger patient with palpable, MRI-visible high-risk disease incl Gleason 5 findings). If not curative treatment for any r…"
  3. distance 0.61: PI-RADS 5, PSA 6.9, PSAD 0.257, age 67, DRE Nodus -> BIOPSY (uncertain). He wrote: "What was the result of the earlier positive biopsy and the MRI precluding that biopsy? Hard to determine what we are looking at here."

PRECEDENT: DEFER (weighted vote 0.25 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using a risk-adapted matrix based on PI-RADS score and PSA density to guide the decision to perform a biopsy. It states, "This risk-based biopsy guidance was confirmed by a cohort study of 2,055 biopsy-naïve men [384]." It further notes that in a pathway where patients with a PI-RADS score of 1-3 and a low-risk profile (PSA-D < 0.15ng/mL/cc, negative DRE, no family history, no ASAP or ISUP1 cancer at prior biopsy) could forgo biopsy while the others underwent combined systematic and MRI-targeted biopsy."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED's suggestion of no biopsy is not decisive because the guideline emphasizes that the decision depends on a risk-adapted matrix involving PI-RADS and PSA density, which are variables that the panel alone does not fully resolve. EXPERT-LIBRARY's precedent of 'DEFER' is not decisive because the guideline suggests that the decision is based on documented prior biopsy grade and surveillance history, which is what the Registrar is tasked to find.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - whether the PSA trend is significant: a rising PSA is a factor that must be considered in the decision
laboratory_results - whether the PSA density is below 0.15ng/mL/cc: this value is a key component of the risk-adapted matrix

THE FOLLOWING VALUES ARE ALREADY KNOWN and a line about any of them is wrong:
age - 65
PSA - 6.22 ng/mL
PI-RADS - 5
PSA density - 0.17 ng/mL²
prostate volume - 36.0 mL
DRE finding - Nodus
prior-biopsy status - Positive
csPCa probability - 0.86727

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on determining the grade of the prior biopsy and the surveillance plan documented in the previous notes, as the guideline suggests this is key.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Determine whether the PSA trend is significant.
  previous_notes (get_previous_notes) -> Determine the grade of the prior biopsy and the surveillance protocol status.
  laboratory_results (get_lab_results) -> Determine whether the PSA density is below 0.15 ng/mL/cc.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What was the grade (Gleason/ISUP) of the prior positive biopsy?
  Q2. Is the PSA trend significant?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Is the PSA density below 0.15 ng/mL/cc?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "focal hypointense area, roughly 18 x 15 mm, situated at the base-to-mid junction of the right peripheral zone."

psa_trend
Determine whether the PSA trend is significant: The PSA trend shows a rise from 2.2 ng/mL (Apr 2022) to 6.22 ng/mL (Jan 2025).

previous_notes
Determine the grade of the prior biopsy and the surveillance protocol status: The notes mention a PSA increase to 5.6 ng/mL on 14 Sep 2024 and a prior biopsy was "Positive". Surveillance protocol status is not explicitly stated as "confirmatory biopsy due" or otherwise.

laboratory_results
Determine whether the PSA density is below 0.15 ng/mL/cc: The laboratory results show a PSA density of 0.17 ng/mL/mL.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes and other data are sufficient to address the immediate decision point.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 score from the mpMRI.
Rising PSA trend from 2.2 ng/mL to 6.22 ng/mL.

AGAINST sampling this patient now
Prior biopsy was positive, meaning tissue diagnosis is already established.
PSA density of 0.17 ng/mL/mL is not below the 0.15 ng/mL/cc threshold.

WHERE THIS LEANS
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.22 ng/mL over 4 points spanning 33 months; velocity +1.21 ng/mL per year; doubling time about 27 months.
PROJECTION at 6 months: 8.7 ng/mL, conformal 95% band 2.5-30.3.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.47
  uncertainty  +/- 0.11 epistemic (95% band 0.26-0.68), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.48  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.47  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.25  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.47 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-STRUCTURED, EXPERT-FUSION, EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: borderline. Weights it expects: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the Registrar appear to have addressed the moderator's questions to the extent possible. The `previous_notes` mentioned a prior positive biopsy but did not explicitly state the grade (Q1), and the `psa_trend` confirmed a significant rise from 2.2 ng/mL to 6.22 ng/mL (Q2). The `laboratory_results` provided a PSA density of 0.17 ng/mL/mL, and the `radiology_report` provided comparison information.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a BIOPSY based on a weighted vote, noting that the documented prior grade was not recorded in the opened documents. The retrieved findings—a rising PSA trend and a PSA density not below the threshold—align with the factors that led the experts to lean towards deferral or uncertainty, but the panel ultimately chose biopsy based on the weighted vote.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What was the grade (Gleason/ISUP) of the prior positive biopsy? This remains unanswered, as the `previous_notes` only stated the biopsy was "Positive."
Q2. Is the PSA trend significant? This was answered by the `psa_trend`, which confirmed a significant rise.

WHAT CARRIES WEIGHT, AND WHY
The most relevant variables for the EAU guideline are the documented prior biopsy grade (to determine if treatment is indicated) and the PSA density (to use in the risk-adapted matrix). The rising PSA trend is also relevant as it reflects disease behavior.

MY SUGGESTION TO THE CHAIR
Given that the critical piece of information—the grade of the prior biopsy (Q1)—is missing, and the PSA density is above the threshold, the guideline suggests a risk-adapted matrix. Since the panel protocol leaned towards biopsy, but the missing data prevents a definitive application of the guideline's criteria, deferral is prudent until the prior grade is known.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

65y male, PSA 6.22, PSAD 0.17, PI-RADS 5, prior positive biopsy, and unrecorded prior grade suggest sampling is warranted. The rising PSA trend and new lesion characteristics pull toward biopsy, despite the lack of prior grade documentation. Initial ISUP not recorded, but the clinical picture favors tissue sampling.

What carried weight: bx=important, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
